Molecular Partners AG (MOLN) AI Stock Analysis

Compare

1 Followers

Top Page

Molecular Partners AG

(OTC:MOLN)

Rating:47Neutral

Price Target:

CHF3.00

▲(0.33%Upside)

Molecular Partners AG's overall stock score is primarily impacted by its financial performance, marked by declining revenues and persistent losses. Technical analysis indicates a bearish trend, while valuation metrics are unfavorable due to ongoing losses and lack of dividends. The earnings call provided some positive insights into pipeline progress, but challenges remain with the loss of a key collaboration.

Molecular Partners AG (MOLN) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap

$117.29M

Dividend YieldN/A

Average Volume (3M)19.30K

Price to Earnings (P/E)―

Beta (1Y)0.43

Revenue Growth-66.82%

EPS Growth4.14%

CountryCH

Employees158

SectorHealthcare

Sector Strength44

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.30

Shares Outstanding40,374,640

10 Day Avg. Volume12,682

30 Day Avg. Volume19,300

Financial Highlights & Ratios

PEG Ratio0.26

Price to Book (P/B)0.83

Price to Sales (P/S)0.00

P/FCF Ratio-1.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$15.00

Price Target Upside401.76% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Molecular Partners AG Business Overview & Revenue Model

Company DescriptionMolecular Partners AG is a Swiss clinical-stage biopharmaceutical company focused on the research, development, and commercialization of a new class of custom-built protein therapeutics known as DARPin® therapeutics. Operating in the biotechnology and pharmaceuticals sectors, the company leverages its proprietary DARPin® technology platform to develop therapies for the treatment of various serious diseases, including cancer and infectious diseases. With a strong emphasis on innovation, Molecular Partners aims to address unmet medical needs through its robust pipeline of product candidates.

How the Company Makes MoneyMolecular Partners AG generates revenue primarily through strategic collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of successfully commercialized products. The company's DARPin® technology platform serves as a key asset in attracting these partnerships, as it offers a versatile approach to drug development that can be applied across multiple therapeutic areas. Additionally, Molecular Partners may receive funding through government grants and research collaborations aimed at advancing its pipeline of drug candidates. The company's revenue model is heavily reliant on the successful development and commercialization of its proprietary therapies, as well as maintaining and expanding its network of strategic partners.

Molecular Partners AG Earnings Call Summary

Earnings Call Date:Mar 06, 2025

(Q4-2024)

% Change Since: -28.47%|

Next Earnings Date:Aug 25, 2025

Earnings Call Sentiment Positive

Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.

Q4-2024 Updates

Positive Updates

Successful Execution of 2024 Program Goals

Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.

Positive Financial Health

The company ended 2024 with a cash balance of CHF 149 million, which supports operations into 2027. They raised CHF 20 million through financing, maintaining a solid financial base with no debt.

Encouraging Clinical Results and Pipeline Progression

The T cell engager 533 showed significant improvements in efficacy with new dosing strategies, resulting in 3 complete responses out of 8 patients treated past day 12.

Negative Updates

Novartis Collaboration Setback

The collaboration with Novartis was not continued as the targets did not progress as expected. This decision was mutual and based on strategic interests.

Revenue Decline from Novartis Collaboration

Revenue decreased as 2024 recognized the last part of the upfront payment from the Novartis collaboration, with no further revenue expected from this source.

Company Guidance

During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.

Molecular Partners AG Financial Statement Overview

Summary

Molecular Partners AG faces financial challenges with declining revenues and persistent losses impacting profitability. While the balance sheet remains relatively strong with low leverage, cash flow issues highlight the need for operational improvements to enhance long-term sustainability.

Income Statement

Negative

Molecular Partners AG has experienced significant revenue declines in recent years, with a sharp drop from 2022 to 2023. The company has negative net and EBIT margins, reflecting ongoing losses. The gross profit margin improved in 2024, but overall profitability remains a concern.

Balance Sheet

Neutral

The company maintains a solid equity position with a high equity ratio over several years. However, there is a significant reduction in stockholders' equity from 2022 to 2024. Debt levels are low relative to equity, indicating limited leverage risk.

Cash Flow

Neutral

Despite a positive operating cash flow in 2022, cash flow has been negative in recent years. Free cash flow has deteriorated, reflecting ongoing cash burn. The company benefits from cash reserves, mitigating immediate liquidity concerns.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.97M	7.04M	189.56M	9.33M	9.34M
Gross Profit	-42.53M	-40.81M	138.81M	-46.39M	-46.73M
EBITDA	-51.63M	-59.52M	117.50M	-60.66M	-59.58M
Net Income	-54.04M	-61.98M	117.85M	-63.78M	-62.76M
Balance Sheet
Total Assets	158.53M	198.35M	262.26M	172.67M	187.55M
Cash, Cash Equivalents and Short-Term Investments	149.44M	186.89M	249.14M	132.81M	173.72M
Total Debt	2.44M	3.65M	4.85M	6.04M	7.22M
Total Liabilities	16.89M	21.92M	27.09M	65.38M	80.33M
Stockholders Equity	141.64M	176.43M	235.17M	107.29M	107.22M
Cash Flow
Free Cash Flow	-59.97M	-59.81M	117.15M	-92.26M	-30.67M
Operating Cash Flow	-59.25M	-59.01M	118.57M	-90.95M	-28.98M
Investing Cash Flow	40.49M	44.64M	-101.12M	-22.24M	-21.75M
Financing Cash Flow	14.43M	-1.17M	-1.57M	50.58M	113.20M

Molecular Partners AG Technical Analysis

Technical Analysis Sentiment

Positive

Last Price2.99

Price Trends

50DMA

3.11

Negative

100DMA

3.35

Negative

200DMA

4.07

Negative

Market Momentum

MACD

-0.05

Negative

RSI

49.76

Neutral

STOCH

70.38

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOLN, the sentiment is Positive. The current price of 2.99 is above the 20-day moving average (MA) of 2.96, below the 50-day MA of 3.11, and below the 200-day MA of 4.07, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 49.76 is Neutral, neither overbought nor oversold. The STOCH value of 70.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MOLN.

Molecular Partners AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (65)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	73 Outperform	CHF663.60M	8.51		―	32.30%	631.04%
Sector *	65 Neutral	CHF27.10B	19.83	9.37%	2.28%	35.94%	-1.97%
NWRN	60 Neutral	CHF140.73M	9.91		―	450.19%	―
IDIA	51 Neutral	CHF513.20M	―		―	11.61%	-356.20%
MOLN	47 Neutral	$117.29M	―	-40.40%	―	-66.82%	4.14%
SANN	41 Neutral	$163.95M	2.58	-93.91%	―	-62.17%	-166.33%

* Healthcare Sector Average

Performance Comparison

CH:MOLN

Molecular Partners AG

2.99

-2.94

-49.58%

CH:BSLN

Basilea Pharmaceutica

53.80

13.80

34.50%

CH:IDIA

Idorsia Ltd

2.93

0.65

28.51%

CH:NWRN

Newron Pharmaceuticals SpA

6.79

-1.11

-14.05%

CH:SANN

Santhera Pharmaceuticals Holding

13.10

3.76

40.26%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 18, 2025